SING GEORGE L sold $20.4M of REGN
SING GEORGE L sold 21,129 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $964.38 ($960.57–$970.18, $20.38M total) across 9 trades on 2026-11-02.
How this was made
The 30-second read
Why it matters
The disclosed $20.4M sale by a director is a material insider transaction that can influence short-term price dynamics.
Market read
The filing introduces fresh, material insider sell data that may prompt short sellers and affect REGN's near-term price.
What to watch
Potential tax-driven liquidation or pre-planned diversification by the director.
Background
SEC Form 4 filings provide direct insider transaction data, often used by traders to gauge insider sentiment.
Ticker impact
Director Sing George L sold $20.4M of REGN shares via open-market transactions on 2026-11-02, disclosed in a Form 4 filing.
likely downward pressure as the market prices in the insider sale
The sale represents a $20M disposition by a key insider, which is material and fresh information.
Market effects
Minimal; the sale does not affect the broader biotech sector.
None; impact confined to REGN investors.
Low; limited to REGN shareholders.
Counterpoint
The sale could be a routine portfolio rebalancing unrelated to company fundamentals.
Key entities
- CompanyRegeneron Pharmaceuticals, Inc.
Biotech firm whose director sold shares.
- PersonSing George L
Director of Regeneron who executed the sale.
